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Abstract
Misfolding and aggregation of proteins is strongly linked to several neurodegenerative diseases, but how such species bring 
about their cytotoxic actions remains poorly understood. Here we used specifically-designed optical reporter probes and live 
fluorescence imaging in primary hippocampal neurons to characterise the mechanism by which prefibrillar, oligomeric forms 
of the Alzheimer’s-associated peptide, Aβ42, exert their detrimental effects. We used a pH-sensitive reporter, Aβ42-CypHer, 
to track Aβ internalisation in real-time, demonstrating that oligomers are rapidly taken up into cells in a dynamin-dependent 
manner, and trafficked via the endo-lysosomal pathway resulting in accumulation in lysosomes. In contrast, a non-assembling 
variant of Aβ42 (vAβ42) assayed in the same way is not internalised. Tracking ovalbumin uptake into cells using CypHer or 
Alexa Fluor tags shows that preincubation with Aβ42 disrupts protein uptake. Our results identify a potential mechanism by 
which amyloidogenic aggregates impair cellular function through disruption of the endosomal–lysosomal pathway.
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Introduction
Neurodegeneration occurs in several diseases that are char-
acterised by protein aggregation, including Alzheimer’s, Par-
kinson’s and Huntington’s disease. In each, there is a strong 
association between the self-assembly of a particular protein 
to form amyloid fibrils and the development or progression 
of the disease [1–3]. However, although this ordered self-
assembly is tightly linked with cell death, precisely what 
constitutes a “toxic” structure, and which molecular mecha-
nisms drive detrimental effects, are still unresolved issues.
In Alzheimer’s disease (AD), the pathological state is 
characterised both by the deposition of tau in neurofibril-
lary tangles, and Amyloid-β (Aβ) into amyloid plaques. 
The self-assembly and accumulation of Aβ, in particular the 
42-residue form [4, 5], is thought to be a very early event 
in the progression of Alzheimer’s disease, occurring before 
changes in tau take place or the expression of cognitive 
impairment [6, 7]. In support of this, compelling genetic 
evidence links Aβ aggregation to AD [8], and prefibrillar 
oligomers of Aβ42 are implicated as critical triggers of 
neuronal cell death [9–11]. Additionally, previous studies 
have shown that synthetic oligomers of Aβ42 cause synaptic 
dysfunction and neuronal death in a range of model systems 
both in vitro and in vivo [1, 12–19].
What is lacking in the current models, however, is a clear 
understanding of the pathway that links Aβ42 aggregation 
with the compromised cell health associated with the disease 
state. Recent work offers an important insight; specifically 
the observation that proteostasis mechanisms, normally 
operating in low pH lysosomes to degrade macromolecules 
and maintain cellular health, appear to be defective in AD 
and other disease states [20–30]. This raises the possibility 
that Aβ might be specifically exerting its toxicity through its 
ability to internalise and affect lysosomal pathways.
Here we investigate this key idea directly, using live fluo-
rescence imaging methods both to characterise the uptake 
and localisation of Aβ42 oligomers in primary hippocampal 
neurons and to assess their impact on the endosomal–lyso-
somal pathway. In particular, we exploit a new pH-sensitive 
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optical reporter to show that Aβ oligomers rapidly inter-
nalise into cells in a dynamin-dependent manner, and then 
traffic directly to lysosomes where they remain for several 
days. Protein misfolding is critical for this outcome since 
a non-assembling Aβ variant undergoes minimal uptake 
and accumulation with the same assay. By imaging events 
occurring in real-time using fluorescent probes, we also 
demonstrate that the presence of Aβ42 disrupts endocytosis 
of other proteins. Our findings provide a key link between 
Aβ42 aggregation and deficits in the endosomal–lysosomal 
pathway, which may account for early events in disease-
related neuronal dysfunction.
Results
Toxic Aβ42 oligomers are internalised in defined 
intracellular compartments
Self-assembly of the Aβ42 peptide into amyloid fibrils is 
strongly linked with neurodegeneration and the subsequent 
symptoms observed in AD [1]. As a starting point, we evalu-
ated the time and dose dependent effect of oligomeric Aβ42 
[15] on cell viability in primary hippocampal neurons using 
the Readyprobes assay (Fig. 1a, b). Compared to buffer 
control, significant differences were observed after incuba-
tion with 10 μM Aβ oligomers at all time points, with an 
increase in cell death from 26.0 ± 3.7% (n total = 1005) to 
65.2 ± 8.2% (n total = 568) (Fig. 1b) from 24 h to 14 days 
incubation respectively. Previous work using an Aβ control 
peptide at the same concentration showed that toxic effects 
are specific to wild type Aβ42 [15]. To examine the pathway 
of action that leads to neuronal cell death, we selected one 
of the intermediate timepoints (3 days, 44% cell death) for 
further experiments.
Initially, we monitored real-time uptake and trafficking 
of Alexa Fluor-conjugated Aβ42 oligomers [15, 16]. Impor-
tantly, our previous work has demonstrated that Alexa Fluor 
labelling does not alter the self-assembly of Aβ42 into oli-
gomers or amyloid fibrils [16] and that the fluorescently 
labelled particles are detected by anti-Aβ antibodies [15]. 
Figure 2a and supplementary movie 1 show the uptake of 
Alexa Fluor 488 labelled Aβ42 oligomers into primary neu-
rons over 15 h. Small fluorescent puncta could be readily 
observed at the 1 h timepoint (Fig. 2a, arrows) and by 5 h 
these were clearly visible in the cytoplasm suggesting that 
oligomers were being internalised via the plasma mem-
brane into intracellular compartments. This continued in a 
time-dependent manner (Fig. 2a–c) and at the 3-day incuba-
tion timepoint, there was extensive accumulation (Fig. 2b, 
arrows) with 100% of cells (n = 72) containing visible Aβ42-
488 puncta in the cell cytoplasm. Additionally, we saw evi-
dence of fluorescence labelling along the cell boundaries 
(Fig. 2b, orange arrowheads), indicative of binding of Aβ42-
488 oligomers to the extracellular membrane.
Aβ42 internalises in a dynamin‑dependent manner 
into lysosomes
To determine the mechanism of Aβ42-488 oligomer uptake, 
we tested whether the observed internalisation is sensitive 
to endocytic blockers using sucrose and chlorpromazine as 
Fig. 1  Aβ42 oligomers cause death of primary neurons in a dose and 
time-dependent manner. a Example widefield images following treat-
ment of cells incubated either with buffer or 10  μM Aβ42 oligom-
ers for 3 days with Readyprobes reagent. Left panels are brightfield 
images showing deteriorated cell morphology in oligomer-treated 
cultures. Right panels are the same region through the green filter, 
showing dead cells labelled with the green reagent, which stains the 
nuclei of cells with compromised plasma membrane integrity. More 
green, i.e. dead cells can be seen in oligomer treated cultures (white 
arrows). b Assessment of oligomer toxicity by Readyprobes cell via-
bility assay. Data shown are averages from three FOV (fields of view) 
in at least three experiments ± SEM (standard error of the mean). 
Unpaired student’s t test; significant differences versus buffer are indi-
cated by *(p < 0.05). DIC differential interference contrast, AFU arbi-
trary fluorescence units
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generic, non-specific inhibitors, and dynasore as a specific 
inhibitor of the GTP-ase, dynamin. It is well-established 
that the protein transferrin endocytoses via clathrin-coated 
pits [31, 32] and this was used as a control protein. Serum-
starved cells incubated for 15 min with Aβ42-488 oligomers 
alone showed bright punctate and diffuse labelling indicative 
of their association with neurons and internalisation (Fig. 2d, 
left panel). However, pre-treatment with any of the endo-
cytic inhibitors yielded a striking reduction in fluorescence 
(Fig. 2d, f) similar to the pattern of distribution in the posi-
tive control, transferrin-488 (Fig. 2e,g). These results sug-
gest that Aβ42 oligomers, like transferrin, are endocytosed 
by a dynamin-dependent mechanism.
Next, we investigated the nature of the cellular structures 
that accumulate Aβ42 oligomers. To confirm the destination 
for Aβ42 oligomers following endocytosis, neurons were 
treated with Alexa Fluor 488-labelled Aβ42 oligomers and 
co-labelled with Lysotracker red (Fig. 3a), an established 
marker of lysosomes. As a control, we used a fluorescent 
conjugate of ovalbumin, a protein known to traffic through 
the endosomal–lysosomal pathway [33] (Fig. 3b). We found 
that both protein signals co-localised with the lysotracker 
fluorescence in compartments around the nucleus, providing 
clear support for the hypothesis that lysosomes are the final 
destination for Aβ42 oligomers. We confirm that untagged 
Aβ42 oligomers also co-localise to lysosomes labelled with 
Texas Red-dextran using an Aβ oligomer specific antibody 
(NU1) (Supplementary Fig. 1). As further support for this 
conclusion, we also examined neurons treated with Aβ42 
oligomers using transmission electron microscopy (TEM). 
Aligned with our fluorescence data we observe the presence 
of large (> 1 μm diameter) round electron-dense vesicular 
Fig. 2  Alexa fluor-488 labelled Aβ42 oligomers are internalised into 
primary neurons by a dynamin-dependent mechanism. a Confocal 
images showing one 0.5 μm z-slice from the middle of the cell body 
of neurons treated with 10 μM Aβ42 oligomers over 15 h. Represent-
ative images from three experiments. Oligomers can be seen associat-
ing with the plasma membrane (white arrows) and internalising into 
the cell. Scale bar is 25 μm. b Magnified example images of cell bod-
ies after 72 h containing Aβ42-488 oligomers in vesicles within the 
cytoplasm (white arrows) and along the plasma membrane (orange 
arrowheads). Representative images from four experiments. One 0.5-
μm z-slice is shown from the middle of the cell body. Scale bar is 
10  μm. c Increase in Alexa Fluor 488 fluorescence intensity within 
the cell body over time. n (cells) 4 h = 14, 24 h = 31, 72 h = 11. Plot 
shows mean ± SEM. Inhibition of uptake of Aβ42-488 oligomers (d) 
or transferrin-488 (e) after 30  min incubation with 0.5  M sucrose, 
10  μM dynasore or 25  μg/mL chlorpromazine. Neuronal nuclei 
stained with DAPI (4′,6-diamidino-2-phenylindole) are shown in blue 
and Aβ42 or transferrin are green. One 0.5-μm z-slice is shown from 
the middle of the cell body. Scale bar is 25 μm. f, g Quantification of 
488 fluorescence intensity from the cell body from three experiments 
normalised to untreated. A Kruskal–Wallis ANOVA was carried out 
followed by pairwise comparisons using Dunn’s test and all were sig-
nificant compared to untreated (*p < 0.05)
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structures in the cell cytoplasm (Fig. 3c, arrows). These 
structures, which were not seen in control neurons (Supple-
mentary Fig. 2), were consistent in appearance with enlarged 
lysosomal structures reported previously in dystrophic AD 
neurons [22, 34–36]. Taken together, these abnormalities, 
specific to oligomer-treated cells, support the conclusion that 
Aβ42 oligomers have a detrimental effect on the cellular 
pathways that end with lysosomal degradation.
A novel pH‑dependent probe provides a real‑time 
assay of Aβ42 uptake into lysosomes
Next, to provide detailed temporal information on the lysoso-
mal fate of oligomers, we developed a novel optical reporter 
that provides a real-time readout of Aβ internalisation into 
acidic compartments. Specifically, we used CypHer5E, a 
commercially available pH-sensitive fluorescent probe, 
which exhibits maximal emission when present in an acidic 
environment [37]. In previous studies this fluorescent moi-
ety has been used to label antibodies for reporting receptor 
internalisation [38] and to tag vesicle proteins for assaying 
exo-endocytic recycling at synaptic terminals [39–41].
The endo-lysosomal pathway is characterised by a shift 
in pH, reducing from ~ 6–7 in early endosomes to ~ 5 in the 
lysosome [42, 43]. Therefore, we hypothesised that a protein 
tagged to CypHer5E that experienced this environmental 
change would yield important temporal information on inter-
nalisation seen as an increase in fluorescence emission, and 
thus allow us to dynamically monitor uptake.
To validate this approach, we conjugated CypHer5E 
with ovalbumin (referred to as Ova-Cy) (Fig. 4a). When 
Ova-Cy was applied to neurons, we observed a time-
dependent increase in punctate fluorescence localised to 
cell bodies, consistent with the presence of this reporter 
in a cellular compartment that undergoes a drop in pH 
(Fig. 4b, d). To corroborate this finding, we also tested 
the effect of pre-treating with  NH4Cl, a weak base that 
increases the pH in the lysosome, prior to the addition 
of Ova-Cy. In this case, a fluorescence increase was not 
observed, confirming that CypHer5E is an effective mon-
itor of basal lysosomal acidification state (Fig. 4c, d). 
Fig. 3  Aβ42 oligomers are trafficked to lysosomes. Co-labelling with 
Lysotracker red shows that Aβ42-488 oligomers (a) localise to lys-
osomes with a similar distribution to 488-labelled ovalbumin (b). 
Orthogonal views also show green and red signal colocalisation in x, 
y and z. Cells were treated with either 10 μM Aβ42-488 oligomers for 
24 h or 100 μg/mL Ovalbumin-488 for 3 h. Scale bar is 10 μm. c (left 
panel) Aligned and overlaid transmission electron microscopy images 
of a section through a neuron treated with 5 μM Aβ42 oligomers for 
14  days showing large circular electron-dense structures (arrows). 
Note, the image is a composite of multiple images that are differen-
tially contrasted to allow clear visualisation of cellular structures. A 
higher magnification of one region of interest (yellow box) is shown 
in the right panel. Scale bar 5 μm (inset 2 μm)
5035Misfolded amyloid‑β‑42 impairs the endosomal–lysosomal pathway
1 3
Moreover, the fluorescence was reduced when  NH4Cl or 
bafilomycin, an ATPase blocker, were added to cells fol-
lowing addition of Ova-Cy (Supplementary Fig. 3). The 
pH-dependence of Ova-Cy emission was confirmed in vitro 
using fluorimetry (Fig. 4e). Specifically, this showed that 
protonated CypHer5E (at low pH) had increased fluores-
cence at the emission maximum (663 nm) compared with 
the non-protonated form (at higher pH) when excited with 
644 nm light, and vice versa, when excited at 500 nm (the 
absorbance maximum for CypHer5E at physiological pH). 
Taken together, our results confirm that CypHer5E is an 
effective optical reporter for monitoring uptake of target 
proteins into acidified structures.
Next, we used the same tagging method to examine the 
fate of internalised Aβ (Fig. 5). Aβ42 was conjugated to 
CypHer5E (Aβ42-Cy, Fig. 5a and Supplementary movie 2) 
and applied to neurons, resulting in an increase in fluores-
cence intensity over a 150-min period, comparable to our 
findings with Ova-Cy (Fig. 5a, c, e). Notably, the distribu-
tion of fluorescent puncta in the cytoplasm was consist-
ent with our observations for both Ova-Cy (Fig. 4b) and 
Aβ42-488 (Figs. 2b, 3a) suggesting that all were localised 
in the same way. CypHer tagged Aβ42 oligomers lead to a 
comparable level of cell death (51%) to untagged oligomers 
(see Fig. 1, 44.8%) and in our previous report ([15], 46.9%) 
(Supplementary Fig. 4).
Fig. 4  Protein-conjugated CypHer5E reports its pH environment. 
a CypHer5E conjugated to ovalbumin fluoresces upon uptake into 
intracellular acidic compartments. b Confocal images showing 
increase in fluorescence 70 min after addition of Ova-Cy to primary 
hippocampal neurons. c No fluorescence increase is observed in cells 
pre-treated with  NH4Cl, a weak base that raises the pH of acidic com-
partments. One 1.0-μm slice is shown. Scale bar is 25 μm. d Quanti-
fication of mean fluorescence intensity from cells shown in b and c. 
Each trace represents an individual cell body either untreated (grey, 
n = 34) or pre-treated with 10 mM  NH4Cl for 30 min (purple, n = 28). 
Data pooled from three independent experiments, 3–4 FOV per 
experiment. Colour bar for look-up table indicates mean fluorescence 
intensity. e Fluorescence arising from Ova-Cy diluted into buffer of 
pH 5.4 (purple) or 7.4 (turquoise). Ova-Cy diluted into buffer con-
taining  NH4Cl, pH 7.4 is also shown (orange). The absorbance maxi-
mum for CypHer5E at physiological pH 7.4 is 500 nm (left plot) and 
at pH 5.4 (similar to the pH in a lysosome) is approximately 645 nm. 
Ova-Cy in acidic (pH 5.4) buffer has increased intensity over neutral 
pH when excited with 644 nm light. The presence of  NH4Cl has no 
effect on the spectral properties of the dye
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To examine whether uptake is specific to prefibrillar mis-
folded forms of Aβ42, or alternatively a generic outcome 
with Aβ proteins, we took advantage of a non-assembling 
form of Aβ42 (variant Aβ42 or vAβ42), which we have 
recently developed as a control peptide [15]. Importantly, 
we have previously demonstrated that this variant structure 
has none of the detrimental effects of Aβ42 with regard 
to neuronal biology or memory formation [15]. As above, 
CypHer5E was conjugated to vAβ42 and applied to cells 
and monitored over 150 min. Compared to cells treated 
with Aβ42-Cy, only a negligible fluorescence increase 
was observed in cultures treated with vAβ42-Cy and no 
change was observed over time (Fig. 5d, e). The toxicity 
of vAβ42-Cy was also examined (25.4%, Supplementary 
Fig. 4) and found to be similar to levels induced by the 
untagged peptide we previously reported (21.7%, [15]).
Aβ42 oligomers inhibit uptake of ovalbumin 
in primary neurons
We have shown that Ova-Cy fluorescence effectively reports 
the pH drop experienced by the protein trafficking through 
the endosomal system to lysosomes. This provides us with a 
powerful assay for monitoring the potential impact of Aβ42 
oligomers on endosomal–lysosomal pathway function. To 
investigate this, cells were pre-treated with Aβ42 oligomers 
before the addition of Ova-Cy. Strikingly, following Aβ42 
exposure, the fluorescence intensity of Ova-Cy was clearly 
lower than cells pre-treated with buffer alone (Fig. 6a–c). To 
ensure these effects were specific to Aβ42 oligomers and not 
just due to general overloading with high concentrations of 
protein, we also performed an additional control experiment 
(Supplementary Fig. 5). Neurons were pre-incubated with 
ovalbumin in place of Aβ42 at the same molar concentration 
(10 μM) for the same duration (72 h). Ova-Cy uptake was 
monitored and no difference observed in the internalised 
Cypher fluorescence intensity compared with buffer, sug-
gesting that it is the Aβ42 oligomers that specifically slow 
the internalisation of Ova-Cy. These results provide strong 
support for a mechanism in which Aβ42 oligomers first traf-
fic to lysosomes and then influence their function.
To examine whether the reduced Ova-Cy fluorescence 
intensity is due to an altered pH or the amount of Ova 
internalised, we also carried out a complementary experi-
ment in which we tagged ovalbumin with Alexa Fluor 488 
(Fig. 6d–f). Analogous to the Ova-Cy experiments, we 
Fig. 5  Live tracking of internalisation of self-assembled Aβ42-Cy 
oligomers into primary neurons and localisation to acidic compart-
ments. a, b Cypher5E was conjugated to either Aβ42 or vAβ42 
peptides and incubated for 2  h, during which time Aβ42 is able to 
self-assemble into oligomers, whereas vAβ42 does not. Following 
addition to primary neurons an increase in fluorescence intensity 
is observed only in cells treated with 10  μM Aβ42-Cy (c) and not 
10 μM vAβ42-Cy (d). One 0.5-μm slice is shown. Scale bar is 25 μm. 
e Quantification of mean fluorescence intensity from Aβ42-Cy 
(red) and vAβ42-Cy (blue) in the cell body (one 0.5 μm slice) over 
150 min. Each trace arises from the same individual cell. Data pooled 
from three separate experiments, 4 FOV per experiment, n (cells) 
Aβ42-Cy = 27, vAβ42-Cy = 42
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observed a robust reduction in fluorescence intensity in cells 
pre-treated with Aβ42 oligomers compared to control, show-
ing that the uptake and trafficking of Ova is impaired. Taken 
together, our findings suggest that the presence of intracel-
lular Aβ42 causes a slowing of the endosomal–lysosomal 
system, which may be important for the mechanism of Aβ42 
toxic action on living cell function.
Discussion
The ordered assembly of peptides and proteins into amyloid 
is strongly linked with neurodegeneration in vivo and in vitro 
[44, 45]. Understanding the cause-and-effect relationship 
between protein self-assembly and neuronal dysfunction 
is challenging since early events are difficult to capture or 
recapitulate. Nevertheless, the case for protein misfolding as 
a cause of neuronal loss is compelling [11, 46–48]. On the 
strongly evidenced premise that misfolded proteins are able 
to damage neurons, we developed an experimental model 
using oligomers of the Alzheimer’s-associated Aβ42 peptide 
in conjunction with novel applications for fluorescent probes 
to explore the link between oligomer exposure and degen-
eration of hippocampal neurons. Benefiting from time-lapse 
imaging of specially engineered optical reporters in living 
neurons, we characterised structural and functional proper-
ties of cells in real-time as a powerful strategy to elucidate 
the underlying mechanisms of aggregated peptide-induced 
neuronal cell death. Initially, we confirmed that the syn-
thetic, pre-fibrillar Aβ42 oligomers were toxic to primary 
hippocampal neurons, consistent with previous findings [1, 
2, 49]. Using fluorescence imaging, we then examined the 
endosomal–lysosomal physiology of individual live cells 
that contained endocytosed Aβ42 oligomers. This real-time 
readout allowed us to reveal dysfunctional mechanisms prior 
to cell death, providing important insights into early events 
that can lead to neurodegeneration. Specifically, we found 
that oligomers are internalised into neurons predominantly 
by a dynamin-dependent mechanism and that these are then 
trafficked to lysosomes and remain intracellular for several 
days.
It is well established that the acidification of lysosomes 
is critical to their function [50]. In order to understand the 
potentially direct effects of Aβ42 oligomers on lysosomal 
function, we developed a method to tag Aβ42 and ovalbumin 
with a pH-sensitive probe (CypHer, Roche) that selectively 
fluoresces in acidic compartments. Using this approach, 
the uptake and localisation of Aβ42-Cy peptides within the 
cell could be monitored in real-time and compared with an 
assembly-incompetent variant of Aβ42. In particular, our 
findings showed that this uptake is specific to self-assem-
bling, wild-type Aβ42.
To explore the downstream effects of accumulated Aβ42 
on the endo-lysosomal pathway, we utilised tagged versions 
of ovalbumin to assay uptake and acidification events in cells 
pre-treated with Aβ42 oligomers. We found that the levels of 
Ova-488 and Ova-Cy fluorescence were markedly reduced 
in Aβ42 treated cells compared to controls, implying that the 
accumulated Aβ oligomers are affecting the endo-lysosomal 
pathway. Because we only considered live cells in this analy-
sis (those with an intact and smooth plasma membrane and a 
clearly defined nucleus, where often nucleoli were visible), 
we can be confident in concluding that the impairment of 
the endosomal–lysosomal system occurs prior to cell death. 
This implicates a potentially catastrophic and ultimately fatal 
effect of Aβ42 on neuronal cells.
How does internalised Aβ42 impair the endosomal–lyso-
somal pathway? We propose that a number of mechanisms 
could conceivably be involved. These include a direct effect 
of Aβ42 on acidification through action on the ATPase [26, 
27], through lysosomal leakage associated with membrane 
interactions [30, 51, 52], or simply through its accumulation 
and overloading of lysosomal proteolytic capacity [53–55]. 
In our study, we clearly demonstrate that a consequence of 
Aβ42 internalisation is an inhibition of further endocytosis 
resulting in a reduction in ovalbumin internalisation. This 
result implies that the oligomers impair the endo-lysosomal 
pathway and thus stall a process critical for cellular health, 
although our experiments do not allow us to definitively 
establish the mechanism by which this outcome arises. Incu-
bating the cells with another, non-toxic, protein did not lead 
to any detrimental effects on endocytosis providing strong 
evidence that it is Aβ42 oligomers specifically that are caus-
ing damage, and not just general endocytic or lysosomal 
burden. It is interesting to note the presence of Aβ42 on the 
extracellular side of the cell membrane, which could provide 
a site for oligomeric binding, or further aggregation [56]. In 
either case, it is conceivable that the accumulation of aggre-
gated proteins along the plasma membrane could perturb 
endocytosis and might be another potential mechanism for 
our observations.
Collectively these results outline a mechanism of Aβ42-
induced cell death that leads to the disrupted endocytosis of 
essential proteins and nutrients. Indeed, they offer a mecha-
nistic basis for previous in vivo studies that have reported 
defects in lysosomal function in neurodegenerative dis-
eases, including the appearance of abnormal lysosomes and 
autophagosomes within dystrophic neurites in human AD 
and mouse model brains [21, 26, 34, 35, 57]. Abnormalities 
to the endocytic pathways in neurons from AD brain tis-
sue have also been observed [58]. Here we have gained key 
information on the specific pathway of action by which mis-
folded proteins exert toxic action on cells whereby uptake of 
Aβ42 oligomers into neurons renders them unable to carry 
out further endocytosis. We suggest that the accumulation 
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Fig. 6  Pre-treating neurons with Aβ42 oligomers inhibits uptake 
of ovalbumin. Cells were treated either with 10  μM Aβ42 oligom-
ers or equivalent volume of buffer for 72 h, followed by addition of 
25 ug/mL Ova-Cy (a) or Ova-488 (d). Quantification of mean fluo-
rescence intensity from Ova-Cy (b) or Ova-488 (e) in the cell body 
(one 0.5 μm slice) over 150 min from cells either treated with buffer 
(blue) or pre-treated with 10 μM Aβ42 oligomers for 72 h (red). Each 
trace arises from the same individual cell measured over time. Data 
pooled from three separate experiments 4–9 FOV per experiment, n 
(cells) buffer = 84, Aβ42 = 19 (b), 4–5 FOV per experiment, n (cells) 
buffer = 53, Aβ42 = 33 (e). Example images of live cells treated with 
Aβ42 oligomers (top) or equivalent volume of buffer (bottom) fol-
lowed by Ova-Cy (c) or Ova-488 (f), taken at increasing time points. 
Fluorescence intensity is only reduced in cells treated with oligom-
ers. Arrows point to neuronal cell bodies. One 0.5-μm slice is shown. 
Scale bar is 25 μm
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of aggregated Aβ42 within lysosomes stalls the endosomal 
system and that this is an early event in oligomer-induced 
neurodegeneration and collectively provides an explanation 




Hexafluoroisopropanol (HFIP) films of recombinant Aβ1-42 
were purchased from rPeptide and vAβ1-42 was purchased 
from JPT Peptide Technologies. Peptides were prepared 
using an adapted protocol [59], which ensures the removal 
of potentially contaminating trace solvents. HEPES buffer 
(10 mM HEPES, 50 mM NaCl, 1.6 mM KCl, 2 mM  MgCl2, 
3.5 mM  CaCl2) was used to mimic the culture media as 
previously described [16, 59, 60]. All preparation was con-
ducted using protein LoBind Eppendorfs and tips (Alpha 
Laboratories). Briefly, 0.2 mg Aβ1-42 (rPeptide) was solu-
bilised in 200 μL HFIP (Sigma-Aldrich) to disaggregate the 
peptide. The solution was then vortexed on high for one 
minute and sonicated in a 50/60 Hz bath sonicator for five 
minutes. HFIP was dried completely using a low stream of 
nitrogen gas. Once completely dried, 200 μL dry dimethyl-
sulfoxide (DMSO) (Sigma-Aldrich) was added, vortexed 
for one minute, and sonicated for one minute. Solutions 
were added to a 7 K MWCO Zeba buffer-exchange column 
(Thermo Scientific) equilibrated with HEPES buffer with 
40 μL HEPES as a stacking buffer. The protein solution was 
kept on ice and the absorbance at 280 nm measured with 
a NanoDrop spectrophotometer using a molar absorption 
coefficient of 1490 M−1 cm−1. Solutions were immediately 
diluted to 50 μM with HEPES buffer and incubated where 
indicated or used immediately in further experiments.
Alexa Fluor conjugated peptides
Peptides were treated as outlined above up to the addition 
of 200 μL dry DMSO. Alexa Fluor tags were prepared as 
per the manufacturer’s instructions (Life Technologies). 
Briefly, 10 μL  dH2O was added to the Alexa Fluor TFP ester 
and kept on ice. This was added to the peptide in 200 μL 
DMSO along with 20 μL 1 M sodium bicarbonate pH 8.3 
to increase the reaction efficiency, mixed and incubated for 
15 min at room temperature protected from light. Follow-
ing this, the procedure resumed as above, and the solution 
was then added to the Zeba buffer exchange column. The 
calculations for the concentration were adjusted to take into 
account the absorbance of the dye.
Cell culture
Rats were housed within a specialised facility under Home 
Office UK guidelines and killed using procedures in accord-
ance with Animals (Scientific Procedures) Act 1986, 
Amendment Regulations 2012 and approved by a local ethi-
cal review panel. Primary neurons were prepared from the 
hippocampus of P0–P1 rats as described previously [61] by 
initially dissecting the tissue into ice cold HBSS contain-
ing 0.1 M HEPES. Following washes in pre-warmed basal 
Eagle’s Minimum (BME) (Gibco) containing 0.5% glucose, 
2% FCS, 1 mM Na-Pyruvate, 0.01 M HEPES pH 7.35, 1% 
Penicillin–Streptomycin, 1% B27 supplement and 1% Glu-
tamax, tissues were triturated using a 1 mL pipette until fully 
dissociated. The cell suspension was diluted further with 
complete BME media and approximately 40,000 cells plated 
into 2  cm2 wells containing a coverslip coated in 20 μg/mL 
Poly-D-Lysine with a layer of hippocampal astrocytes that 
had been growing for 4–5 days. After 2–3 days, cells were 
treated with 3.25 μM cytosine arabinoside to curb further 
proliferation of astrocytes. Experiments were carried out on 
cells 10–14 DIV (days in vitro).
Cell viability assay
After the desired incubation time, one drop of each Ready-
Probes reagent (Life Technologies) was added to cells in 
500 μL of media. The kit contains a blue stain to label all 
cells, and a green stain to label dead cells only. Cells were 
incubated at 37 °C for 15 min and then imaged using wide-
field fluorescence microscopy with a Zeiss Cell Observer 
widefield microscope fitted with a Hamamatsu ORCA 
camera and a Nikon Plan Fluor 10X NA 0.3 air objective. 
DAPI fluorescence was captured using a G 365 excitation 
filter and a LP 420 emission filter with a FT 395 dichroic. 
Green fluorescence was captured using a FITC filter set (BP 
450–490 excitation filter, BP 515–565 emission filter and 
FT 510 dichroic). Identical acquisition settings were used 
for all experimental and control samples. Images were ana-
lysed using FIJI. Neuronal cell bodies were identified using 
DIC and DAPI channels (astrocytes were excluded), which 
indicated total cell number (live and dead). Those that were 
also fluorescent in the FITC channel were defined as dead. 
The numbers of dead cells were expressed as a percentage of 
the total number of cells. At least three fields of view were 
imaged per sample in each experiment. Each experiment i.e. 
using newly prepared peptide added to different cultures, 
was performed at least three times.
Aβ42 oligomer uptake and blocking
All imaging experiments outlined below were carried 
out using a Leica SP8 confocal microscope and image 
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processing using FIJI. For overnight imaging, the Adaptive 
Focus Control feature was used to maintain constant focal 
planes throughout the course of the experiment. Where mul-
tiple fluorescent probes were imaged, samples were scanned 
sequentially to prevent spectral bleedthrough.
To monitor live uptake, neurons were plated on top of a 
layer of astrocytes in poly-D-Lysine coated 35 mm dishes 
with 1.5 coverslips (Mattek) and cultured for 10–14 days. 
Fluorescent- tagged oligomers were added and cells imaged 
live using a 63 × numerical aperture (NA) 1.2 oil objective. 
The environment was maintained at 37 °C with humidified 
 CO2.
For blocking experiments, cells plated on coverslips in 
24-well plates were washed with warm external bath solu-
tion (EBS; 137 mM NaCl, 5 mM KCl, 3 mM  CaCl2, 1 mM 
 MgCl2, 10 mM D-Glucose and 5 mM HEPES pH 7.3) then 
serum starved for 1 h in 500 μL warm EBS. To block endo-
cytosis, cells were treated with one of the following for 
30 min: 0.5 M sucrose, 10 μM Dynasore (Sigma), 25 μg/
mL chlorpromazine or left untreated. After blocking, fluo-
rescently labelled Aβ42 oligomers were added, or 100 μg/
mL transferrin-488 as a control to confirm blocking effects. 
After incubation for 30 min, cells were washed 3–4 times 
quickly with warm EBS, fixed using 2% paraformaldehyde 
(PFA) in EBS for 15 min, rinsed with PBS then the coverslip 
mounted onto a glass slide using Prolong Gold with DAPI 
(Life Technologies). Fixed cells were imaged with a 40 × NA 
1.1 water objective.
Lysosome labelling
Ovalbumin-488 was purchased from Life Technologies and 
reconstituted in PBS to a stock concentration of 5 mg/mL 
Hippocampal neurons plated on Mattek dishes were treated 
with Ova-488 to a final concentration of 100 μg/mL for 3 h 
or Aβ42-488 oligomers to 10 μM for 24 h, then 100 nM 
Lysotracker red (Life Technologies) was added, incubated 
for 1.5 h and imaged using a 100 × oil objective.
For experiments using NU1 and Texas Red-Dextran, neu-
rons were incubated with Aβ42 oligomers for 24 h then with 
0.5 mg/mL 10,000 MW Texas Red-Dextran (ThermoFisher) 
for 1 h. Cells were washed twice with fresh media and incu-
bated with neuron-conditioned media for a further 3 h to 
chase into lysosomes. Cells were then fixed with 0.3% PFA, 
permeabilised with 0.025% saponin, blocked with Super-
block (ThermoFisher) containing 0.025% saponin and then 
labelled with NU1 (courtesy of the William Klein labora-
tory) and goat anti-Mouse Alexa Fluor 488 conjugated sec-
ondary (Invitrogen) both diluted in wash buffer (25% Super-
block in PBS) at 1:500. Coverslips were mounted in Prolong 
Gold containing DAPI and imaged using a Leica confocal 
SP8 microscope.
Transmission electron microscopy
Cells grown on coverslips were washed once with EBS then 
fixed in 2% paraformaldehyde, 2% glutaraldehyde in PBS 
for 15 min at room temperature. The fixative was replaced 
with 100 mM glycine and incubated for 1 h followed by a 
1 min wash in 100 mM  NH4Cl. Cells were then washed 
twice with 0.1 M sodium cacodylate buffer before a second 
fixation step in 1% osmium tetroxide with 1.5% potassium 
ferrocyanide in sodium cacodylate for 1 h. Following repeat 
rinses with 0.1 M sodium cacodylate, 10 mg/mL tannic acid 
was added (45 min) to stabilize and enhance contrast, before 
a further incubation in 10 mg/mL anhydrous sodium sul-
phate (5 min). The cells were rinsed with water (5 repeats) 
and dehydrated using increasing concentrations of ethanol 
(50%, twice with 70%, twice with 90% then three times with 
100%, 5 min each). The coverslips were then transferred into 
a 1:1 mixture of polypropylene oxide and EPON resin for 
1 h, then moved into pure EPON resin (Electron Microscopy 
Sciences) (exchanged after 2 h) and left overnight. The fol-
lowing day, the coverslip was placed cell-side down onto an 
EPON block and dried at 60 °C overnight until polymer-
ised. The coverslip was removed by submerging in liquid 
nitrogen and the block sectioned (70 nm thickness). Sections 
were viewed on a JEOL transmission electron microscope 
(100 kV).
Conjugation of CypHer5E to ovalbumin and Aβ 
peptides
CypHer5E Mono NHS Ester (Roche) was prepared as per 
the manufacturer’s instructions. Briefly, 100 μL of dimethyl 
sulphoxide (DMSO) was added to 1 mg CypHer5E and the 
solution sonicated in a 50/60 Hz bath sonicator for 15 s. 5 
μL of dye was diluted into 4 mL PBS-sodium bicarbonate 
(0.5 M) pH 8.3 and the absorbance at 500 nm measured. The 
concentration of dye was calculated based on a molar extinc-
tion coefficient of 40,000. Chicken egg white albumin was 
purchased from Sigma and dissolved to a concentration of 
10 mg/mL in water. The concentration was confirmed using 
absorbance readings at 280 nm and an extinction coefficient 
of 32,176. The solution was diluted to 1 mg/mL in PBS-
sodium bicarbonate (0.5 M) pH 8.3 and a 20-M excess of 
CypHer5E dye added. The solution was protected from light 
and gently agitated on a rocker for 1 h. Following the label-
ling reaction, unconjugated dye was separated and removed 
from the solution using a purification column packed with 
BioGel P-30 fine size exclusion purification resin (BioRad), 
which is designed to separate free dye from proteins with a 
molecular weight of greater than 40,000 kDa (MW ovalbu-
min = 45,000 kDa). Elution buffer (10 mM potassium phos-
phate, 150 M sodium chloride pH 7.2) was run through the 
column and once excess buffer had drained into the column 
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bed the reaction mixture was added, allowed to enter into 
the resin, then eluted using elution buffer. The labelled pro-
tein (Ova-Cy) was collected and the concentration of protein 
and dye measured using a Nanodrop spectrophotometer. The 
stock solution was kept at 4 °C for a maximum of 3 months. 
For Aβ42 and vAβ42, labelling with CypHer5E was per-
formed using a protocol similar to the Alexa Fluor labelling 
method described previously. CypHer5E dye was prepared 
as described above and a 20 M excess added to the peptide 
dissolved in 200 μL DMSO along with 20 μL 1 M sodium 
bicarbonate pH 8.3. Briefly, the reaction mixture was incu-
bated for 15 min, then applied to a Zeba buffer-exchange 
column equilibrated with HEPES to remove the DMSO and 
free dye. The protein and dye concentrations of the eluted 
solutions were measured, diluted to 50 μM (protein), incu-
bated for 2 h to form oligomers (for WT Aβ42) and then 
diluted to working concentration.
Live‑cell imaging of neurons treated with CypHer5E 
conjugated proteins
Neurons were plated on 35 mm Mattek dishes as described 
previously. After 10–14 DIV, cells were either treated with 
Aβ42 oligomers, Ova-Cy, Aβ42-Cy, vAβ42-Cy or an equiva-
lent volume of HEPES buffer. All imaging was carried out 
live in media at 37 °C with humidified  CO2 using a 1.4 NA 
HC PL APO CS2 63 × oil objective with a 633-nm laser 
line and fluorescence emission collected between 650 and 
700 nm with a PMT detector. For experiments assessing pH 
dependence of CypHer, Ova-Cy was added to a final con-
centration of 10 μg/mL with or without 50 mM  NH4Cl and 
imaging started. For experiments monitoring a decrease in 
fluorescence,  NH4Cl was added to a final concentration of 
50 mM or bafilomycin to 1 μM and imaging continued. For 
experiments where cells were pre-incubated with Aβ42 or 
vAβ42, Ova-Cy was added to a final concentration of 25 μg/
mL. For all CypHer analyses, where one 0.5 μM z-slice has 
been analysed, a focal plane in the middle of the cell that 
contained none or a negligible proportion of saturating pix-
els within the cell body was selected from the image that had 
maximal fluorescence. Focal planes in images at other time 
points were matched to this slice to ensure the same focal 
plane of the cell was being monitored and mean fluorescence 
intensity calculated. A region of interest was drawn around 
the cell body excluding the nucleus. The mean fluorescence 
intensity in either one z-slice or a maximum projection 
image of several slices at each time point was measured in 
each cell body. All cells within a given FOV were analysed. 
Where images are displayed, LUTs were matched for each 
image within an experiment. All analysis was carried out 
using FIJI. Graphs and statistical analysis were prepared in 
GraphPad Prism.
Fluorimetry
19 mM Ova-Cy stock solution was diluted tenfold into EBS 
that had a pH of either 5.4 or 7.4 when it contained 10 mM 
 NH4Cl. Scans were collected on a Varian Cary Eclipse fluor-
imeter. Samples were excited at either 500 nm or 644 nm 
and emission collected from 650 to 800 nm. Excitation and 
emission slit widths were set to 5 nm, and the scan rate was 
600 nm/min with 1 nm data intervals and an averaging time 
of 0.1 s.
Significance statement
The misfolding and aggregation of proteins is intimately 
linked with many neurodegenerative diseases. This manu-
script reports the use of a new optical probe to establish how 
prefibrillar, oligomeric forms of the Alzheimer’s associated 
peptide, Aβ42, bring about damaging effects in primary 
neurons. We demonstrate that CypHer-Aβ42 oligomers are 
rapidly taken up into cells in a dynamin-dependent manner 
and trafficked via the endosomal–lysosomal pathway result-
ing in accumulation in lysosomes. Preincubation with Aβ42 
influences the subsequent uptake of other proteins, indica-
tive of impairments in endo-lysosomal mechanisms. Here we 
dynamically monitor the cellular response to the presence 
of Aβ42 oligomers in primary neurons and establish a new 
link between Aβ42 aggregation, uptake and deficits in the 
endosomal–lysosomal pathway.
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